Areas Hit by Hurricanes Prepare for Mosquito Storm - Zika - West Nile - Chikungunya & Dengue fever expected to rise in the aftermath of all the hurricanes

https://www.healthline.com/health-news/areas-hit-by-hurricanes-prepare-for-mosquito-storm#1

Read the whole Document carefully and you will find that it is a Big Deal!

Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions

https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf

I saw the 8k come out at the start of the conference and listened / viewed slides but the reality of the significance of the FDA designation for the Hemopurifer in the Expedited Access Pathway (EAP) Program really wasn't stressed or highlighted. Sounded just like it was submitted for "designation" but not yet fully accepted into the program. IMO JJ dropped the ball on this one and should have gone into detail what the designation actually means for the use of the hemopurifier and the benefits to the Company in Helping to move it ahead to full approval & marketing.

Maybe I missed something but I listened & it didn't convey as a Big Deal to me at the time but after reading details of the program I've come to think that it is. Plus the fact that 58k shares traded & it was up 25% to 1.998 all from 3:15 to 4:00 during & after the Rodman/Renshaw presentation today seems to agree that it is something substantial.

Any thoughts? TIA

https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393978.pdf

Updated PRX302 PC Ph2a Results Abstract Poster

Presented at EAU17 in London Today

http://eau17.uroweb.org/scientific-programme/overview/session/prostate-cancer-is-the-future-focal/8870/

Take note that since recent Roth Presentation partial response patient results have been raised from 7 to 9 patients or a 28% increase in response.

Thanks & you are very Welcome

Fellow NewYorker but mostlyunwanted LOL

Yes share price held steady for 6 months Recent filings since Jan 11, 2017 are all SC 13G/A Each has it's own reason & purpose but none of them reflect increased ownership.

http://investor.sophirisbio.com/sec.cfm?DocType=&DocTypeExclude=&SortOrder=FilingDate%20Descending&Year=&Pagenum=1&FormatFilter=&CIK=

Last two are required to be filed by today to show activity last year by FMR LLC & Boxer Capital & show that they own -0- shares

Previous 3 from Empery, Sabby & CVI show reduction of ownership from over 5% to just under 5% This action eliminates their voting rights on Company business matters and allows them to exercise any warrants they have once share price passes $4 which is the price set on the warrants when issued by SPHS. The reason could very likely be because the Company has been marketed by Oppenheimer and is preparing itself for a possible upcoming Sale.

Hope that Helps you understand & Best to you NY

What is it that you think you see?

New 6-K filed Normal trading resumes TASE next regular trading day Sunday Feb 12th:

http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11377453&type=HTML&symbol=KTOV&companyName=Kitov+Pharmaceuticals+Holdings+Ltd.&formType=6-K&dateFiled=2017-02-09

Nice recovery today Let's keep it going!

Best to All

dp

Great info re: FDA, SEC Disclosure: Standard Procedures especially relevant could be the section >communicating with the investing public< in relation to Issac's open mouth policy

https://www.law360.com/articles/28107/fda-sec-disclosure-standard-procedures-can-help

Another recent case of a public disclosure investigation of a drug company (AVEO) but this one in US by SEC to view just as an example.

https://www.sec.gov/news/pressrelease/2016-59.html

Sorry No Time suggest you access slide show for presentation and visit discussion going on KTOV board @ stocktwits

Best to all

dp

Listening to Q&A now

So far great presentation Slide show at the link below:

http://seekingalpha.com/article/4038606-kitov-pharmaceuticals-ktov-investor-presentation-slideshow

They are in an extended quiet period due to the ongoing negotiations that Oppenheimer was contracted for. If Oppy was done the company would have to announce it because it would be considered a material change of events. At this point the company can't say anything to shareholders either individually or collectively until the negotiations are finalized or Oppenheimer is finished doing what they were contracted to do which is exploring strategic alternatives for SPHS and topsalyisn.

Anyone that doesn't either trust management or thinks that this is an invalid reason for managements silence always has the option of selling their shares.

Best to all Longs

dp

Wondering why No mention of NT157 in PR?

Seems to be still in TyrNovo Company coffers

>Researchers discover novel double dagger anti-cancer agent<:

https://medicalxpress.com/news/2015-11-dagger-anti-cancer-agent.html

Researchers discover a novel double dagger anti-cancer agent
November 10, 2015

Alexander Levitzki receiving the European Federation of Medicinal Chemistry's prestigious Nauta Award for Pharmacochemistry.

Cancer is a highly complex disease in which the tumor recruits its surrounding tissue, as well as the immune system to support and promote its own growth. This realization explains why tumor therapy has been difficult for physicians. Researchers now realize that not only does the tumor need to be targeted, but also its microenvironment and the immune system, which is subverted by the tumor to support it.

Two studies in the October 2015 print journal, Ocogene, focus on new potential drug-treatment research through a careful study of, and link between, colorectal cancer and melanoma.

Long-time cancer researcher Alexander Levitzki, Wolfson Family Professor Emeritus of Biochemistry at the Hebrew University of Jerusalem, and his senior colleagues, Efrat Flashner-Abramson and Dr. Hadas Reuveni, and other colleagues, describe a double-edged molecule known as NT157 and its action against metastatic human melanoma. In an accompanying article in the same journal, Prof. Michael Karin, a highly acclaimed scientist from the University of California, San Diego, in collaboration with Prof. Levitzki's laboratory, shows the dramatic therapeutic effects of NT157 on colon cancer in a mouse model, which faithfully mimics the human disease.

This unique family of compounds inhibits the action of proteins within the tumor itself, the action of these two cancer-driving proteins in the cancer-supportive microenvironment, as well as the action of "pro-tumor" immune cells, according to Prof. Levitzki. These molecules target two different proteins, comprised of a completely different mechanism of action.

A family of small organic molecules, which fulfills these aims, was developed by the Hebrew University's Alexander Silberman Institute of Life Sciences, in collaboration with the oncological pharmaceutical company, TyrNovo, which licensed NT157 from the Yissum Research Development Company of the Hebrew University of Jerusalem. In his five decades of cancer research, Prof. Levitzki has been the recipient of many international awards, including the Wolf Prize for Medicine.

As part of the NT157 research, the mechanism of these molecules was deciphered by Flashner-Abramson as part of her Ph.D. thesis in the Levitzki laboratory, and by Dr. Reuveni, CEO of TyrNovo (and previously NovoTyr Therapeutics Ltd.). These molecules target two different proteins, comprising of a completely different mechanism of action.

This action was highly unexpected and unforeseen.

Dr. Elza Sanchez-Lopez, from UC San Diego Prof. Karin's lab, conclusively shows that due to the dual targeting feature of NT157, both the tumor and conducive microenvironment became suppressed; a highly effective activity against colon cancer.

"The understanding that cancer is a manifestation of signal transduction gone awry has led to the development of 'targeted therapy' or 'signal transduction therapy,' aimed at cancer-driving proteins," according to the paper, formally titled "Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling."

Signal transducer and activator of transcription 3 (Stat 3) is a protein that has attracted much interest as a target for anti-cancer drugs. Stat 3 is a member of a family of seven latent cytoplasmic proteins (organisms such as bacteria, which lack a cell nucleus) and that function as key mediators of cytokine (small proteins) and growth factor signaling.

In the second paper, titled "Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling," researchers looked at the tumor microenvironment (TME). TME exerts critical pro-tumorigenic effects through cytokines and growth factors that support cancer cell proliferation, survival, motility (capability of movement), and invasion.

Colorectal cancer (CRC) is the third most commonly diagnosed cancer, with more than 1.2 million cases each year in the United States. While improved early detection and patient stratification (categorization), results in a significant reduction of mortality, most improvement has been limited to early stage CRC. In patients with advanced stages of the disease, morbidity and mortality remain high.

Tumor development is highly dependent on intricate interactions between multiple cell-types, in addition to malignant epithelial (membranous tissue covering internal organs and other internal surfaces of the body) cells that harbor oncogenic mutations. As in the case of melanoma, anti-cancer drugs for CRC are frequently ineffective against cancer-cells that are therapeutic target which concomitantly affect the malignant behavior of cancer cells and the supportive function of the TME is of particular importance.

Therapies that target TME components in addition to cancer cells should have strong anti-tumor activity.

A prospective study of a cohort of 210 CRS patients shows that tumor size and depth of invasion significantly correlate with IGF-1 and IGF-1R, an insulin-like growth deficiency.

Specific signal transduction inhibitors, a category of anti-cancer drugs that inhibit the enzymes essential to the growth and survival of cancer cells while causing little or no damage to non-cancer cells, are rarely effective in treating the disease. In most cases, tumors possess primary drug resistance due to their inherent heterogeneity – one of the underlying reasons that make treatment of cancer difficult. Resistance to drugs is due to genomic instability and acquisition.

"Our results strongly support further clinical evaluation of NT157 and similar compounds in sporadic human CRC," according to the paper's authors

Explore further: Study links genetic mutation and melanoma progression

More information: E Flashner-Abramson et al. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling, Oncogene (2015). DOI: 10.1038/onc.2015.229

E Sanchez-Lopez et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling, Oncogene (2015). DOI: 10.1038/onc.2015.326

Journal reference: Oncogene search and more info website

Provided by: Hebrew University of Jerusalem search and more info website

Read more at: https://medicalxpress.com/news/2015-11-dagger-anti-cancer-agent.html#jCp

>Inhibition of IGF-1 signaling promotes proteostasis
by enhancing protein aggregation< Quite impressive indeed:

http://media.wix.com/ugd/9ff08c_4487a205bf7a4efbb69731c0cb65e261.pdf

Nice add for JW Asset

Looks like close to $5 million more invested in ARLZ

They must know something...

Thanks commoncents

dp

Very disappointing...

Share price and sector was finally gaining some traction after 6 months and close to a 50% decline for ENSV and wham DILUTION!

And right back down again. Hopefully this will be back up fairly quick with the sector strengthening.

Seems anytime things start looking better is the exact right time to bail...

Best to All

dp

Do you have a Link or a source to support your statement?

>>The company has reportedly commenced putting in place the people and locations necessary for the next phase 2b prostate cancer trial, to go off either year end or early 2017<<

Seems that you must have read or heard of it somewhere since you say it was reported.

Thanks in Advance

dp

Let's see if you can still tell us that After the Buyout... LOL

Sorry, but I don't Think you have a clue one way or the other.

Enjoy! dp

Below is a Link to the Show Series

You'll have to see if you can find the segment yourselves. Hopefully you can and it wasn't an "interview" it had a little of Kim Thompson and a lot about the science behind Kraig Biocraft and what I guess was footage from their lab and nature.

I watch these "kids" science and nature shows every Saturday (3hrs) while putzing around and have found out some really remarkable information that I then look up & research more. It's usually New & pretty much cutting edge stuff.

If you're older like me (64) you must know that you gotta keep up with the kids whether you have any or not...

http://www.xplorationstation.com/nature-knows-best

Best to All again.

dp

Kim Thompson CEO & Co on Fox5 NY Now

Saturday Morning -Kid's TV show- called "Xploration Nature Knows Best" Nice explanatory segment on KBLB about 5-7 minutes long. Try & catch it if you can.

I'm not an investor here but have had it on my Watch list forever and thought you guys and gals would appreciate the Heads Up.

Best of Luck to All you here

dp

ARLZ Director Seth Rudnick just picked up 30,000 shares

Looks like things are really starting to percolate here. Insider buying is always a Good thing to see!

Best to All dp

Aralez Pharmaceuticals Inc. director just picked up 30,000 shares

Seth Rudnick, a director of Aralez Pharmaceuticals Inc., recently acquired 30,000 shares of the company. The buys took place at $4.77 per share, on November 11, 2016. Rudnick now owns 94,391 shares of the company. Rudnick operates out of Mississauga, A6. Some additional info was provided as follows:

This transaction was executed in multiple trades at prices ranging from $4.69 to $4.8299. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

Other recent filings from the company include the following:

Aralez Pharmaceuticals Inc. director just picked up 1,000 shares - Nov. 15, 2016
Aralez Pharmaceuticals Inc. Just Filed Its Quarterly Report: ... - Nov. 8, 2016
Aralez Pharmaceuticals: Aralez Reports Third Quarter 2016 Financial Results - Nov. 7, 2016
Entry into a Material Definitive - Nov. 4, 2016

http://www.conferencecalltranscripts.org/4/summary2/?id=3244116

ALBO up 12%+ on EMA (PRIME) acceptance

First News from newly merged Company getting some well deserved attention.

Best to All dp

http://ir.albireopharma.com/releasedetail.cfm?ReleaseID=999534

Albireo’s Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agency’s PRIME Program
Program designed to speed up evaluation of investigational medicines for diseases with unmet medical need

BOSTON, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that its lead product candidate, A4250, has been granted access to the PRIority MEdicines (PRIME) program of the European Medicines Agency (EMA) for the treatment of progressive familial intrahepatic cholestasis (PFIC).

“PFIC is a highly debilitating genetic liver disorder that is life altering for affected children and their families,” said Ron Cooper, President and Chief Executive Officer of Albireo. “There is an urgent need for an effective pharmacological treatment for PFIC, as there are currently no approved drug options in the United States or Europe. A4250’s acceptance into the PRIME program serves as validation of its promise to meet that need. We look forward to collaborating with the EMA on the development plan for A4250, as well as the potential accelerated assessment of A4250 in Europe.”

The PRIME program was launched by the EMA to provide enhanced support to developers of investigational medicines that target an unmet medical need, with a focus on those that may offer a major therapeutic advantage over existing treatments or address a disease with no current treatment option. The program is designed to provide early engagement with the EMA to optimize development plans and speed up evaluation, with the goal of helping patients benefit as early as possible from therapies that may significantly improve their quality of life. As of August 2016, only 13 out of 57 requests for PRIME eligibility had been accepted into the program. Having been accepted into the program, A4250 may be eligible for accelerated assessment of a potential future marketing authorization application (MAA) in Europe.

A4250 is currently being evaluated in children with chronic cholestasis in a Phase 2 clinical trial that is intended to support a potentially pivotal clinical trial in PFIC planned to be conducted in the United States and Europe. Albireo anticipates meeting with the U.S. Food and Drug Administration (FDA) regarding the planned PFIC trial in the first quarter of 2017.

About A4250
A4250 is a first-in-class product candidate in development for progressive familial intrahepatic cholestasis (PFIC) and potentially other orphan pediatric cholestatic liver diseases. A4250 is a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), has minimal systemic exposure and acts locally in the gut. A4250 is currently being evaluated in children with chronic cholestasis in a Phase 2 clinical trial that is intended to support a potentially pivotal clinical trial in PFIC.

About Progressive Familial Intrahepatic Cholestasis
Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic disorder that causes progressive, life-threatening liver disease, which may start early after birth or at a young age and rapidly progress to end-stage liver disease. Three alternative gene defects have been identified that correlate to three separate PFIC subtypes, known as types 1, 2 and 3. The precise prevalence of PFIC is unknown, but PFIC has been estimated to affect between one in every 50,000 to 100,000 children born worldwide.

PFIC is commonly associated with elevated serum bile acids. Prominent symptoms of PFIC include pruritus, which is associated with severe sleep disturbance and diminished overall quality of life, and poor growth. First-line treatment in PFIC is typically off-label ursodeoxycholic acid (UDCA). Notwithstanding treatment with UDCA, many PFIC patients will require partial external biliary diversion (PEBD) surgery and ultimately liver transplantation. Although success rates vary, published third-party studies have shown that PEBD surgery can slow, and in some cases stop, the progression of liver disease and lead to reduced pruritus and improved sleep.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Info regarding CBS News Celebrex Study:

Taken from the comments section of this News Release:

http://www.cbsnews.com/news/celebrex-arthritis-nsaid-drug-study-surprises-cardiovascular-heart-experts/

Comments: nucjo68 1 hour ago

Approximately 24,000 patients were studied. 69% dropped out (16,560) and 2.5% died (600). Safety based on data from 6,840 individuals who continued. Not such a large overall sampling size

**********************************************************

KIT-302 still better and safer than celebrex. This is just protection and posturing by Pfizer and Generic Manufacturer's to protect their revenue stream.

Best Week to All. dp

AstraZeneca spinoff starts trading as ALBO 11/4/2016

Nov 3, 2016

Albireo Completes Transaction with Biodel to Create Publicly Traded Company Focused on Orphan Pediatric Liver Diseases

— Albireo Pharma, Inc. to trade on The NASDAQ Capital Market under symbol “ALBO” —

— Company to develop novel bile acid modulators to treat orphan pediatric liver diseases, other liver and gastrointestinal diseases —
http://ir.albireopharma.com/releasedetail.cfm?ReleaseID=997477


BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators through its operating subsidiary, today announced the completion of the share exchange transaction between Biodel Inc. (NASDAQ:BIOD) (through November 3) and Albireo Limited and its shareholders and noteholders, effective as of November 3, 2016. The combined organization will be called Albireo Pharma, Inc. and will commence trading on The NASDAQ Capital Market on November 4, 2016 under the symbol “ALBO.”

Completion of the share exchange, together with $10 million in new capital invested prior to the closing by existing Albireo Limited investors, provides approximately $30 million to enable Albireo to advance development of its pipeline, including its lead product candidate, A4250, in development for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC is a life-threatening orphan liver disease that affects young children.

“The completion of the share exchange is an exciting step in the evolution of Albireo as we enter the public markets with funding expected to be sufficient to progress A4250 into a planned pivotal trial in PFIC, which we anticipate starting next year,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We believe A4250 has the potential to become a much needed, nonsurgical treatment option for children suffering from PFIC or other rare cholestatic liver diseases.”

On November 3, 2016, prior to the closing of the share exchange, Biodel completed a one-for-thirty reverse stock split. As a result of the reverse stock split, every 30 shares of Biodel common stock outstanding immediately prior to the share exchange was combined and reclassified into one share of Biodel common stock. No fractional shares are being issued in connection with the reverse stock split. Instead of fractional shares, cash will be issued based on the closing price of Biodel common stock on The NASDAQ Capital Market on November 2, 2016.

The holders of ordinary shares of Albireo Limited immediately prior to the share exchange received 0.06999 shares of Biodel common stock in exchange for each ordinary share. This exchange ratio reflects the reverse stock split. Following the reverse stock split and the share exchange, Albireo has approximately 6,294,725 shares outstanding.

The combined organization will operate under the leadership of Albireo’s officers, including: Ron Cooper, President and Chief Executive Officer; Jan Mattsson, Chief Operating Officer; Tom Shea, Chief Financial Officer and Treasurer; Paresh Soni, Chief Scientific Officer; and Pete Zorn, Senior Vice President, Corporate Development and General Counsel. The board of directors of the combined organization is comprised of seven members, including five directors from Albireo Limited’s former board, David Chiswell, Ph.D., Michael Gutch, Ph.D., Heather Preston, M.D., Denise Scots-Knight, Ph.D., and Mr. Cooper, and two directors from the former Biodel board, Julia R. Brown and Davey S. Scoon. Dr. Chiswell is the new Chairman of the Board. The combined organization’s corporate headquarters are in Boston, Massachusetts.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo traces its origins to a spinout from AstraZeneca in 2008.

Albireo is located in Boston and its wholly owned direct and indirect subsidiaries are located in London and Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Biodel / Albireo Reverse Merger Complete! New Symbol ALBO

Albireo Completes Transaction with Biodel to Create Publicly Traded Company Focused on Orphan Pediatric Liver Diseases
GlobeNewswire•November 3, 2016

https://finance.yahoo.com/news/albireo-completes-transaction-biodel-create-153000218.html

— Albireo Pharma, Inc. to trade on The NASDAQ Capital Market under symbol “ALBO” —

— Company to develop novel bile acid modulators to treat orphan pediatric liver diseases, other liver and gastrointestinal diseases —

BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators through its operating subsidiary, today announced the completion of the share exchange transaction between Biodel Inc. (BIOD) (through November 3) and Albireo Limited and its shareholders and noteholders, effective as of November 3, 2016. The combined organization will be called Albireo Pharma, Inc. and will commence trading on The NASDAQ Capital Market on November 4, 2016 under the symbol “ALBO.”

Completion of the share exchange, together with $10 million in new capital invested prior to the closing by existing Albireo Limited investors, provides approximately $30 million to enable Albireo to advance development of its pipeline, including its lead product candidate, A4250, in development for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC is a life-threatening orphan liver disease that affects young children.

“The completion of the share exchange is an exciting step in the evolution of Albireo as we enter the public markets with funding expected to be sufficient to progress A4250 into a planned pivotal trial in PFIC, which we anticipate starting next year,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We believe A4250 has the potential to become a much needed, nonsurgical treatment option for children suffering from PFIC or other rare cholestatic liver diseases.”

On November 3, 2016, prior to the closing of the share exchange, Biodel completed a one-for-thirty reverse stock split. As a result of the reverse stock split, every 30 shares of Biodel common stock outstanding immediately prior to the share exchange was combined and reclassified into one share of Biodel common stock. No fractional shares are being issued in connection with the reverse stock split. Instead of fractional shares, cash will be issued based on the closing price of Biodel common stock on The NASDAQ Capital Market on November 2, 2016.

The holders of ordinary shares of Albireo Limited immediately prior to the share exchange received 0.06999 shares of Biodel common stock in exchange for each ordinary share. This exchange ratio reflects the reverse stock split. Following the reverse stock split and the share exchange, Albireo has approximately 6,294,725 shares outstanding.

The combined organization will operate under the leadership of Albireo’s officers, including: Ron Cooper, President and Chief Executive Officer; Jan Mattsson, Chief Operating Officer; Tom Shea, Chief Financial Officer and Treasurer; Paresh Soni, Chief Scientific Officer; and Pete Zorn, Senior Vice President, Corporate Development and General Counsel. The board of directors of the combined organization is comprised of seven members, including five directors from Albireo Limited’s former board, David Chiswell, Ph.D., Michael Gutch, Ph.D., Heather Preston, M.D., Denise Scots-Knight, Ph.D., and Mr. Cooper, and two directors from the former Biodel board, Julia R. Brown and Davey S. Scoon. Dr. Chiswell is the new Chairman of the Board. The combined organization’s corporate headquarters are in Boston, Massachusetts.

About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo traces its origins to a spinout from AstraZeneca in 2008.

Albireo is located in Boston and its wholly owned direct and indirect subsidiaries are located in London and Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Three Big Biotech Movers: Insider Monkey

http://www.insidermonkey.com/blog/here-are-three-big-biotech-movers-and-our-take-on-whats-next-483757/

Here Are Three Big Biotech Movers And Our Take On What’s Next
Published on October 28, 2016 at 11:20 am by Market Exclusive in Market Movers,News,Stock Analysis

Finally, Biodel Inc (NASDAQ:BIOD).

This one isn’t as straightforward. To simplify the situation, Biodel is looking to merge with a private company called Albireo. The two are hoping to combine in what is essentially a reverse merger for Albireo using Biodel as a vehicle through which to gain a quick NASDAQ listing. If it is succesfull, the combined entity will focus on diseases of the liver, and attempt to push forward a pipeline that comprises primarily Albireo’s assets.

However, in order for the deal to go through, Biodel needs to persuade its shareholders that it is in their interests, and these shareholders need to vote by way of a proxy to approve the merger. The company set up an annual meeting at which it had hoped to gain enough votes to push the merger though, but by the proposed date, it was unable to secure said requirement.

As such, the meeting has now been delayed and pushed back to November 3. Between now and then, Biodel will be contacting investors essentially begging them for their vote. The company is down from a market cap perspective, based on this fact.

We think, however, that the vote will eventually go through, as while it’s not a great exit for investors, it’s better for them than Biodel Inc (NASDAQ:BIOD) pushing forward alone with a diminished pipeline.

"stinky pinky"? surely you jest. As I see it the problem here is fear of the unknown by "investors" that lack both the understanding and the patience required when you invest in an startup that is breaking new ground. I don't think that Long term and knowledgeable shareholders sold into it much yesterday. They either held tight or bought more. I sat pat as I'm fairly full with no available cash.

Flippers and traders use a different mentality and that combined with the Drugs/Biotech & election time worries is IMHO Why? the sell off. Seems obvious that the shares are for protection and NOT dilution.

Best to all dp

Annual Meeting Adjourned (again) until Thursday, November 3

Guess nervous nellies, short term flippers and capital preservationists are bailing. I'm in with a .27 average and will continue to hold till the outcome. No sense in bailing now with the potential merger and possible share price increase so close. To me; It's worth the risk. Gotta be in it to win it.

For the size of the drop the volume isn't that unusually heavy and level II shows more bids than asks.

Best to all dp

http://finance.yahoo.com/news/biodel-announces-intent-further-adjourn-231800003.html

Biodel Announces Intent to Further Adjourn Annual Meeting until Thursday, November 3
[PR Newswire]
October 26, 2016

DANBURY, Conn., Oct. 26, 2016 /PRNewswire/ -- Biodel Inc. (BIOD) ("Biodel") announced today that, assuming it has not received from stockholders sufficient proxies to approve the matters necessary to complete its proposed combination with Albireo Limited pursuant to a previously announced share exchange agreement prior to 8:30 a.m. local time on Thursday, October 27, 2016, it intends to again adjourn its 2016 Annual Meeting of Stockholders ("Annual Meeting"), now scheduled for October 27, 2016, without any business being conducted. In that circumstance, Biodel intends to adjourn the Annual Meeting to 8:30 a.m. local time on Thursday, November 3, 2016, at the offices of Wiggin and Dana LLP, Two Stamford Plaza, 281 Tresser Boulevard, Stamford, Connecticut 06901 (the "Further Adjournment").

Biodel notes the following important considerations.

The Further Adjournment would be intended to allow additional time for stockholders to vote on the proposals set forth in Biodel's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on September 19, 2016. As of October 26, 2016, proxies have been submitted by stockholders representing approximately 49.83% of the outstanding shares of Biodel common stock outstanding and entitled to vote at the Annual Meeting, meaning that almost 32.2 million shares remain unvoted.

In particular, the Further Adjournment would be intended to allow additional time for Biodel's stockholders located in Germany and elsewhere in Europe to contact their banks and brokers to request proxy materials and to provide voting instructions to those banks and brokers. There is a significant number of shares that Biodel understands to be held by stockholders in Europe that have not yet been voted.

Biodel reminds all of its stockholders, even those who may have already voted, that the proposed combination with Albireo cannot be completed without approval of both "Proposal No. 1" (share issuance) and "Proposal No. 2" (reverse stock split), each as described further below. Of the proxies received as of October 26, 2016, approximately 94.13% are in favor of Proposal No. 1, and approximately 88.67% are in favor of Proposal No. 2, reflecting widespread support for the combination.

If the proposed combination with Albireo does not close, the Biodel board of directors may decide to sell or otherwise liquidate the various assets of Biodel. If Biodel decides to dissolve and liquidate its assets, there can be no assurances as to the amount or timing of any available cash that may be left to distribute to stockholders after paying the debts and other obligations of Biodel and setting aside funds for reserves. This would also result in the loss of significant effort and expense incurred to date in pursuing the proposed combination with Albireo.

If the Further Adjournment is implemented as intended, Biodel does not anticipate making a further announcement as to the adjournment.

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

Please call Morrow Sodali at (800) 662-5200 or +44 (0)20 71006451 for voting assistance.

The Annual Meeting has been called for the following purposes: (1) to consider and vote upon a proposal to approve the issuance of shares of Biodel common stock pursuant to the Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel, Albireo and Albireo securityholders ("Proposal No. 1"), (2) to effect a reverse stock split of Biodel common stock in the ratio of one new share for every 30 shares outstanding ("Proposal No. 2"), (3) to approve a new equity incentive plan for use by Albireo Pharma, Inc. from and after the closing of the proposed transaction, (4) to elect two Class III directors for a term of three years and (5) to consider and vote upon an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of Proposals No. 1-4.

The record date for the Annual Meeting remains September 16, 2016. Biodel stockholders as of the September 16, 2016 record date can vote, even if they have subsequently sold their shares. Biodel's board of directors and management respectfully request all such holders as of the record date to please vote your proxies as soon as possible.

No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. BIODEL STRONGLY ADVISES ALL OF ITS STOCKHOLDERS TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS RELATING TO THE ANNUAL MEETING BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS ARE AVAILABLE AT NO CHARGE ON THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT WWW.SEC.GOV. In addition, copies of the Proxy Statement and other documents may be obtained free of charge by accessing Biodel's website at www.biodel.com or by contacting Biodel's Corporate Secretary at 203-796-5000 or by mail at Investor Relations, Biodel Inc., 100 Saw Mill Road, Danbury, Connecticut 06810. If the number of additional shares voted is not sufficient to approve the proposals, Biodel intends to adjourn the Annual Meeting again, which may be costly.

Voting Instructions

All stockholders as of the September 16, 2016 record date can vote, even if they have subsequently sold their shares, and Biodel encourages stockholders to do so before November 2, 2016 at 11:59 p.m. Eastern Time. Stockholders are reminded that their vote is extremely important and are urged to complete, sign, date and mail the proxy card at their earliest convenience. Stockholders may also submit a proxy by telephone or via the Internet by following the instructions printed on the proxy card.

About Biodel

Biodel Inc. is a specialty biopharmaceutical company. More information about Biodel is available at www.biodel.com.

Additional Information and Where You Can Find It

Biodel filed a definitive proxy statement with the SEC on September 19, 2016 in connection with the solicitation of proxies for its 2016 Annual Meeting of Stockholders and has mailed the definitive proxy statement and other relevant materials to Biodel's stockholders. At the 2016 Annual Meeting of Stockholders, Biodel's stockholders will be asked to approve, among other things, a proposal for the issuance of Biodel's common stock in the previously announced proposed transaction with Albireo. BIODEL'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN CONNECTION WITH THE SOLICITATION OF PROXIES FOR BIODEL'S 2016 ANNUAL MEETING OF STOCKHOLDERS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT BIODEL, ALBIREO AND THE PROPOSED TRANSACTION. These documents and other documents filed by Biodel can be obtained free of charge from the SEC's website at www.sec.gov. These documents also can be obtained free of charge by accessing Biodel's website at www.biodel.com or by contacting Biodel's Corporate Secretary at 203-796-5000 or by mail at Investor Relations, Biodel Inc., 100 Saw Mill Road, Danbury, Connecticut 06810.

Participants in Solicitation

Biodel, Albireo, their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Biodel's stockholders in connection with Biodel's 2016 Annual Meeting of Stockholders under the rules of the SEC. Information about these participants, and a description of their direct and indirect interests, by security holdings or otherwise, may be found in the definitive proxy statement that Biodel filed with the SEC on September 19, 2016 relating to its 2016 Annual Meeting of Stockholders. The definitive proxy statement was mailed to all stockholders of record as of the record date set for the 2016 Annual Meeting of Stockholders and can also be obtained free of charge from the sources indicated above. Other information regarding participants in the proxy solicitation may be contained in other relevant materials filed by Biodel with the SEC.

After a round-a-bout circle jerk I was finally able to vote for the BIOD/ALBO merger tonight. I ended up getting the Control # needed to vote from my Broker (e-trade) after they sent me on a wild goose chase yesterday that eventually brought me back to them with a (better) customer service representative than the one that sent me away chasing rainbows yesterday.

Got the Control # and voted with no problem at

https://central.proxyvote.com/pv/web

Best to all dp

I never got (or misplaced??) the Proxy Statement so I called etrade trying to get it done.

They said to go to Biodel Investor Relations to get a Control # @

http://investor.biodel.com/

and then use that to place Vote @

https://central.proxyvote.com/pv/web

Just sent Biodel IR Contact a question asking for this number using the link above.

Will update board if I make any progress or get a reply.

"Better late then never"... Seems to apply here. When I couldn't find it I just said well it's only 10,000 shares and shouldn't make any difference but it seems like they want (or need?) every vote they can get so like they say:

> Get out and Vote if you already haven't <

Out of curiosity - Anyone else "missing" their proxy mailing??

Best to all dp

Common prostate cancer treatment linked to dementia risk

http://www.cbsnews.com/news/prostate-cancer-treatment-adt-hormone-therapy-dementia-risk/

Common prostate cancer treatment linked to dementia risk

By Mary Brophy Marcus CBS News October 13, 2016, 2:45 PM

A new study is adding to the evidence that a common prostate cancer treatment may raise a man’s risk for dementia.

Researchers from the University of Pennsylvania and Stanford found that a type of hormone therapy called androgen deprivation therapy (ADT) may double the risk of developing dementia.

ADT is used to reduce levels of male hormones called androgens in the body and helps shrink prostate cancers. Androgens, including testosterone, stimulate the growth of prostate cancer cells. Most androgens are made by the testicles.

Testosterone has been shown to be important for the health of neurons, the nerve cells that carry “messages” in the brain. Because previous studies have linked ADT to Alzheimer’s and other problems associated with brain health, the scientists wanted to take a close look at its relationship with dementia, said study author Dr. Kevin Nead, a resident in the department of radiation oncology at the Perelman School of Medicine at the University of Pennsylvania, and a fellow at Penn’s Leonard Davis Institute of Health Economics.
Prostate cancer treatment linked to Alzheimer's
Play Video
Prostate cancer treatment linked to Alzheimer's

“We thought that these treatments, because they lower testosterone, could negatively impact neurological health globally and we were interested in seeing if ADT is linked with dementia,” Nead told CBS News.

He and colleagues analyzed data from the medical records of 9,272 men who were diagnosed with prostate cancer between 1994 and 2013. None had been diagnosed with dementia ahead of the study. Their aim was to see who developed any type of dementia – senile dementia, vascular dementia, frontotemporal dementia or Alzheimer’s.

They also looked at the risk over time and found that the absolute increased risk of dementia after five years was 7.9 percent among men who’d undergone ADT treatment compared with 3.5 percent in those who hadn’t had the hormone therapy.

“The relative risk, comparing people who didn’t get the treatment to people who did, there was more than a doubling of risk,” Nead said.

The study, published today in JAMA Oncology, also showed that the prostate cancer patients who’d received ADT for a year or longer had a higher risk for cognitive problems, and so did men over the age of 70.

The researchers adjusted for a variety of variables, including ethnicity, diabetes, cardiovascular disease, cancer, what medications the men were taking, and lifestyle habits such as smoking.

Dr. Paul Wright, chair of the department of neurology at Long Island Jewish Medical Center, in New Hyde Park, New York, and North Shore University Hospital, in Manhasset, New York, told CBS News that it’s “a very informative study, very well done and very interesting.”

“The study overall showed that there was an increase of dementia in a short period of time. And they also showed the longer you’re on it, for one year and above, and the older you are, there is more of a likelihood you’re going to have dementia,” he said.

ADT is a very common treatment, he noted, saying more prospective studies are needed to answer additional questions about how it impacts cardiovascular and other aspects of neurological health – factors which are tied to dementia.

“It raises a lot of questions about how we manage these patients. I don’t think it’s so straightforward and cut-and-dried. There’s more to this than just saying this will result in Alzheimer’s disease,” said Wright, noting that hormone therapy does increase survival in patients.

Nead said it’s hard to find accurate numbers on just how many men undergo hormone therapy for prostate cancer, but he said, “Generally, the number is around 500,000 men in any given year get ADT. Around 50 percent of men who have prostate cancer will at some point get ADT.”

Do oncologists now have an obligation to tell their prostate cancer patients the risks of dementia when they recommend hormone therapy? And will the results change treatment recommendations?

“It’s a tough question. I think, big picture, there are multiple studies even before this one that suggest ADT might be associated with cognitive changes. The current study definitely supports that. Based on the body of literature that exists now, it would be beneficial to talk to patients about cognitive risks,” Nead said.

But he said he wouldn’t recommend changing treatment plans until further prospective studies are conducted – studies that could follow patients over a long period of time to track neurocognitive and other health changes.

I think more lost their shares than got them during that bear raid.

That's generally how it works. Retail looses their shares, MM's & Institutional accumulators take their shares and everybody that counts is Happy!

Hands up if you "scored" any KTOVW warrants below $2 today? and Hands down if you lost your warrants below $2 today... As if we didn't already know the reality.

You won't get robbed if you don't show your hand and say "Take it Please"...

Best to all. dp

KTOVW #8 Percentage Gainer on NASDAQ

Kitov Pharmaceuticals Warrants > KTOVW 2.3798 +0.38 +19.00% Open 2.00 High 2.55 Low 2.00 Vol 394.17k

http://quotes.freerealtime.com/rt/frt/M?SA=Percent%20Gainers&IM=stats&stat=3

Here's Why BIOD is up 25% in the last 2 days...

And is up 143% from a low close for the year of (0.24 in January) to today's close at (0.585)

Actually, the attached article isn't the whole story but it sure seems enough of a reason to raise a lot of interest... and BIOD share price too.

Some additional reasons Why? BIOD is surging ahead is that it recently won a judgement against UNIS (Unilife Corporation) for "Failure to Deliver" on a pivotal clinical trial contract along with the fact that the BIOD pipeline will be sold prior to the ALBO reverse merger as it doesn't fit into the New companies area of interest and the proceeds will be distributed to existing BIOD shareholders.

Quite a trifecta for continued share price appreciation as I see it.

Best to All and Enjoy! dp

http://www.insidermonkey.com/blog/heres-why-biodel-inc-biod-just-gained-and-what-it-means-478828/

Here’s Why Biodel Inc (BIOD) Just Gained, And What It Means

A small cap biotech named Biodel Inc (NASDAQ:BIOD) based out of Connecticut just logged close to 20% gains yesterday. At first glance, there’s very little to support the move. Dig a bit deeper, however, and things become clear. The company is set to merge with a Japanese company called Albireo Limited near term, and once the merger completes, the two will trade under BIOD (at least, initially, then change it to ALBO) but Albireo’s name.

The operations of the new entity will continue as the shared operations of the two legacy companies, so it stands to reason that some positive news for Albireo would – by proxy – be positive for Biodel Inc (NASDAQ:BIOD).

So, it’s something related to Albireo that drove the action – right?

That’s right.

The company just announced that it had met the primary endpoint from a phase III clinical trial of its lead chronic constipation candidate, elobixibat – a trial conducted in the company’s native Japan. If the drug can pick up an FDA approval, and we’re pretty certain this is the motive behind the merger – in essence, it’s basically a reverse merger to avoid a NASDAQ IPO – then there’s a potentially large upside for the newly formed entity.

With this in mind, let’s have a look at the drug in question, and attempt to put a value on an approval.

As mentioned, the drug is called elobixibat, and it is targeting chronic constipation. It is part of a family of drugs called selective IBAT inhibitors, and it is essentially an attempt to leapfrog the current standard of care treatments in the space by reducing the side effects associated with treatment. How does it do this? Well, the majority of the current SOCs are systematic, and perform their primary function in the small intestine. In contrast, elobixibat operates locally in the colon. Its primary mechanism of action is to block reabsorption of bile acids from the small intestine into the liver, and by doing so, increase secretion and motility, countering the negative symptoms of this chronic condition.

The phase III in question was targeting a primary endpoint of a change in the number of weekly spontaneous bowel movements (SBMs), specifically, a marked increase, from baseline to the first treatment week compared with placebo.

The trial hit this endpoint with a high degree of statistical significance, while also hitting on a number of secondary endpoints – change in frequency of complete SBMs, time to first SBM, severity of constipation and stool consistency, and a few more – and maintaining a low degree of intolerability.

The only real adverse events were mild, and pretty much fell in line with expectations – a few patients with diarrhea, some abdominal pain, that sort of thing. Nothing severe, and not in more than around 13% of patients.

So what’s next?

Well, we expect the company to wait until it closes on the merger before acting on the data with the FDA and submitting a registration application. As such, we are looking to this merger as the next major catalyst. Once that completes, which the two companies expect it will before the close of the fourth quarter, we will look for an NDA submission, and subsequent acceptance, by the agency, as a secondary revenue driver.

Beyond that, of course, it’s all about PDUFA.

So, to go back to our initial question, what are the chances of approval, and what is the size of the market on an FDA green light?

We think the chances of approval are high based on the latest data, and that the company should have no problem getting an authorization approved. Of course, this is subject to the standard levels of uncertainty at this end of the biotech space, but right now we don’t see anything that is hindering its chances. From a market perspective, the CIC space was worth a little over $I.6 billion last year, and is expected to hit $2.5 billion by 2022.

The primary risk here is capital. Neither company has too much cash on hand, and a CIC push is going to require a high degree of initial marketing capital. This points to a near-term raise, which in turn, points to some dilution at some point during early next year. If the company can execute a marketing strategy successfully, there’s no reason why this raise (and dilution) can’t be mitigated, but it has to be consideration for an early-stage investor.
Note: This article is written by Mark Collins and was originally published at Market Exclusive.

$BIOD Now @ $.519 +0.053 +11.37% on 83,000 shares in After Hours trading.

Finally the BIG MOVE UP is being made!

http://www.nasdaq.com/symbol/biod/after-hours

CDC: NY leads nation in Zika cases, with 811 testing positive

Me, Rooting for the virus? You've got to be kidding. Please point to any words I've posted that even come anywhere near to supporting that statement. You can't because I never said or implied any such thing. I'm just countering your erroneous post that says "It's All Blowing Over"... Miami neighborhood declared Zika Free by CDC.

Well Good for them but How short sighted of you. One neighborhood that has sprayed the mosquito's and everything else into oblivion is now safe, at least from the Zika carrying Aedes Aegypti mosquito and probably all the other bugs both bothersome and beneficial that live there. And at what cost to the health of the human and animal population residents? Only time will tell...

You are a despicable and evil minded and untruthful person. I doubt that you even know a lifeguard that has saved more than one life in a day. Please post a reference link to one let alone multiple lifeguards that you "know" as you say that have saved "more lives in a day" than this "sham" as you call it ever will. TRUTH? No, just another bunch of lies just like all the rest of the BS that you post.

And for your information, Here's the Latest CDC Report that attests to the FACT that contrary to your reports - It's NOT ALL BLOWING OVER:

http://www.newsday.com/news/health/cdc-ny-leads-nation-in-zika-cases-with-811-testing-positive-1.12390408?pts=379339

CDC: NY leads nation in Zika cases, with 811 testing positive

Updated September 30, 2016 10:23 PM
By Candice Ferrette candice.ferrette@newsday.com

Please visit link above for additional pictures, maps and video links

New York continues to lead the nation in Zika cases, with 811 people testing positive for the mosquito-borne virus, according to figures released Friday by the U.S. Centers for Disease Control and Prevention.

Florida ranked second with 731 cases, including 59 patients who were infected locally, in Miami — the only state where this has occurred to date.

All of New York’s Zika cases were related to travel, according to the CDC.

“New York has a large population of persons who hail from areas currently experiencing local transmission,” said Dr. Susan Donelan, an infectious-disease specialist at the Stony Brook University School of Medicine.

Travelers might have been exposed to the virus and qualify for testing once they are back home in New York, Donelan said.
DataNY leads in rate of Zika cases

The virus has been linked to brain damage and serious birth defects in infants born to infected mothers.

More than 25,000 cases of Zika infection have been reported in the United States and its territories, and of those, more than 2,000 cases are in women who are pregnant, CDC officials said.

Congress this week approved a $1.1 billion supplemental spending package to fund research and prevention efforts after about seven months of partisan wrangling. President Barack Obama on Thursday signed the bill, which funds federal goverment operations until Dec. 9.

“Zika is still a real threat — and we have more to do — but it is good news that Congress was finally able to do what we have been asking for months and fund critical efforts to beat back the virus,” Sen. Chuck Schumer (D-N.Y.) said in a statement.

Zika is primarily spread to people through the bite of infected Aedes mosquitoes. In most cases the symptoms are mild and can include fever, rash, joint pain and red eye.
HealthZika virus and 10 other major outbreaks

Health experts are particularly concerned about the impact on pregnant women and couples who might conceive.
@Newsday

“If a sexual partner has traveled to areas with local transmission, partners should follow the guidance from the CDC and either avoid sexual relations altogether or consistently and correctly use condoms,” Donelan said.

CDC officials on Friday also released new recommendations urging men who might have been exposed to Zika to wait at least six months before trying to conceive a child with their partners.

There is currently no vaccine and no medicine to treat Zika. Health officials urge pregnant women to avoid traveling to areas with a high number of Zika infections, particularly South America, Central America and the Caribbean.

The best way to prevent infection is by wearing long-sleeved shirts and pants, using insect repellent and sleeping under mosquito nets to prevent bites, health officials said.

Re: Zika/Utah

>>there has been one local case of transmission confirmed in Utah. How it passed from father to son in that case was a mystery, but in the New England Journal of Medicine, researchers now say it likely passed through sweat or tears. That would make it the first case transmitted in that manner. The father, who eventually died from the disease -- the only American case to do so -- had a virus level 100,000 times higher than typical Zika patients.<<

Too bad that they didn't both either have a visionary Doctor or likely the time frame available to get this father authorized to be hooked up to the Aethlon hemopurifier as Dr Michael Mawanda, who was saved from ebola death was. This is exactly Why? this next broad spectrum experimental approval of the Aethlon Hemopurifier is so crucial and critical.

Dr. Mawanda’s miraculous recovery from Ebola:

http://www.newvision.co.ug/new_vision/news/1316079/dr-mawanda-miraculous-recovery-ebola

But then again, the Zika virus, according to our resident "SH" expert, is reported to be all "blowing over" and not really a problem at all anymore as he has also reported are all the other "inconvenient" viral pathogens that are constantly constantly popping up and morphing away from the testing of conventional treatment protocols and killing people. According to his previously referenced "experts" Five years is about the average time frame from viral birth to it's natural demise.

So What's the big deal? What's that to Worry about??

The Black Death or Black Plague was one of the most devastating pandemics in human history, resulted in the deaths of an estimated 75 to 200 million people and peaked in Europe in the years 1346–53. (Which is 7 years and at a time when the World population and contagion possibilities, due to travel, were a mere fraction of what they are Today.)

https://en.wikipedia.org/wiki/Black_Death

So sad that this Aethlon and JJ hater doesn't have the capabilities or the compassion to understand the realities of this situation and that regardless of anything; The Aethon Hemopurifier must continue on to prove itself. Billions are being spent chasing down the illusive individual and constantly changing viral strain when the embedded lectin and hemopurifier process might be able to capture much of the whole crowd... That's what the continuous testing is all about.

Best weekend to all and RIP to another medical visionary, Dr. Dale B. Schenk

dp

Re: AVE ATQUE VALE DALE SCHENK

Oh my... Seems so sudden to his "medical leave" announcement.

God Bless him for all the people he devoted his life in trying to Help. The World just lost a great humanitarian and medical visionary whose works will continue on to benefit many.

King James Bible - 2 Timothy 4:7
I have fought a good fight, I have finished my course, I have kept the faith:

Rest in Peace Dale. You have finished your course well....

In Memoriam - Friend, Scientific Innovator and Leader Dr. Dale B. Schenk has Passed Away

GlobeNewswire•September 30, 2016


DUBLIN, Ireland, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), announced today that its Co-founder, President and Chief Executive Officer, Dr. Dale B. Schenk, passed away this morning, after confronting his pancreatic cancer with the same courage, determination and humor that pervaded all areas of his life.

"Dale was a dear friend and colleague, and the broader scientific community has lost an incredibly innovative and creative leader," stated Lars G. Ekman, MD, PhD, Chairman of the Prothena Board of Directors. "Dale will be remembered not only for his pioneering work in protein immunotherapy that laid the foundation for many of today`s most promising therapeutic approaches, but also as a courageous scientist and business leader with a terrific sense of humor. His infinite energy and passion for applying scientific discoveries toward the development of new medicines for untreatable diseases leaves a lasting legacy to science and patients, and will continue to inspire us. On behalf of the Board of Directors, Prothena management team and employees, we deeply mourn his loss and extend our sympathies to his family."

The Board is meeting shortly regarding succession and an announcement will follow.

Dr. Schenk began his career as a researcher and pioneered the immunotherapeutic approach for the treatment of protein misfolding diseases, as exemplified by Alzheimer`s disease; his groundbreaking approaches to understanding neurological diseases have brought about advances in the broader pharmaceutical industry.

Over the course of his career, Dr. Schenk inspired and mentored dozens of scientists, and his approach to research and development was characterized by creativity, collaboration, and determination. Under his leadership at Prothena, the Company has advanced a new class of protein immunotherapies that seek to fight devastating diseases including AL amyloidosis and Parkinson`s disease. Prior to founding Prothena, Dr. Schenk was executive vice president and chief scientific officer of Elan. Notably, he was the lead researcher on Elan`s experimental vaccine designed to fight Alzheimer`s, with groundbreaking work that earned him the coveted Potamkin Prize from the American Academy of Neurology (AAN). When he won the award, it was the first time that the honor had been bestowed on an industry scientist.



DALE SCHENK - ROCK STAR OF SCIENCE (Click for Rock Star Picture)

I totally agree that sticking with Dexcel & Royalties is the First and most desirable option.

Look how long the Patent protection is for. Why give up all the years of long term gains that this can give for a pittance in the short term?

Makes no sense and in the end, much, much less dollars...

Hold & Stay Strong and Trust that management will choose and do the Best thing for themselves and their shareholders.

Enjoy! dp

Sometimes it's OK to want to shoot the messenger...

Although he wasn't as bearish with his analysis as he usually is, it's exposing his following of attack Bears that's the concern here even though IMHO they can't DO ANYTHING TO STOP this train.

And regarding KTOV & KTOVW today, tomorrow and so on; Just forget CT's "stair steps" always first analysis. High Rise Stocks are just like High Rise Buildings: That's what they invented elevators for... Rapid ascension!

Best to all Longs

dp